drugset / Trial / NCT00486980

Intramuscular Peramivir for the Treatment of Uncomplicated Influenza

NCT00486980 ↗

Phase 3 Withdrawn BioCryst Pharmaceuticals
RandomizedParallel-groupDouble-blind

Summary

This is a multinational, randomized, double-blind study comparing the efficacy and safety of two single dose regimens of peramivir administered intramuscularly versus placebo in adults with uncomplicated acute influenza.

Timeline

Start
—
Primary completion
—
Completion
—

Outcome

Outcome not reported

Stopped: “This study was withdrawn for administrative reasons. The dose ranging plan for the program was revised".”

Drugs

EvaluationDrugModalityDoseRoute
Subject PERAMIVIR ANHYDROUS Small molecule 150 mg Intramuscular
Subject PERAMIVIR ANHYDROUS Small molecule 300 mg Intramuscular

Indications